-
Cancer screening with multicancer detection tests: A translational science review CA: Cancer J. Clin. (IF 254.7) Pub Date : 2024-03-22 Wendy S. Rubinstein, Christos Patriotis, Anthony Dickherber, Paul K. J. Han, Hormuzd A. Katki, Elyse LeeVan, Paul F. Pinsky, Philip C. Prorok, Amanda L. Skarlupka, Sarah M. Temkin, Philip E. Castle, Lori M. Minasian
Multicancer detection (MCD) tests use a single, easily obtainable biospecimen, such as blood, to screen for more than one cancer concurrently. MCD tests can potentially be used to improve early cancer detection, including cancers that currently lack effective screening methods. However, these tests have unknown and unquantified benefits and harms. MCD tests differ from conventional cancer screening
-
Multicancer detection tests: What we know and what we don’t know CA: Cancer J. Clin. (IF 254.7) Pub Date : 2024-03-22 Sam M. Hanash, Peter P. Yu
The concept of blood-based multicancer early detection (MCED) tests has generated much excitement, in part because of the potential of such tests to reduce cancer mortality by encompassing cancers for which screening is currently not available. A review in this issue of CA: A Cancer Journal for Clinicians, largely authored by members in the Division of Cancer Prevention at the National Cancer Institute
-
Study identifies risk factors that may lead to secondary cancers CA: Cancer J. Clin. (IF 254.7) Pub Date : 2024-03-13 Mike Fillon
“Second primary cancer occurs with different frequency depending on the site of the first cancer, and we find a higher cumulative incidence in cancer sites with a relatively good or good survival. To the best of our knowledge these results are useful in the counselling of patients with cancer and the data provide new evidence for personalized survivorship care.” Trille Kristina Kjaer, PhD A study using
-
Issue Information CA: Cancer J. Clin. (IF 254.7) Pub Date : 2024-03-13
No abstract is available for this article.
-
Is mandated genetic counseling needed? CA: Cancer J. Clin. (IF 254.7) Pub Date : 2024-03-13 Mike Fillon
With genetic testing becoming more readily available for cancer prevention and surveillance, a new study investigated whether skipping counseling—either before or after testing—is any worse than requiring counseling for patients with a family history of cancer or those known to be at genetic risk for cancer. The results of Making Genetic Testing Accessible (MAGENTA), a four-armed randomized clinical
-
Erratum to “Cancer statistics, 2024” CA: Cancer J. Clin. (IF 254.7) Pub Date : 2024-02-16
This erratum corrects the following: Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. doi:10.3322/caac.21820 Multiple errors appear in Table 9. The first age column should be “1–19” (not “1–9” as originally published), and the second age column should be “20–39” (not “20–30”). Additionally, cancer was left off as the fourth leading cause of death among
-
Neoadjuvant chemotherapy for advanced oral cavity cancer CA: Cancer J. Clin. (IF 254.7) Pub Date : 2024-02-08 Dan Yaniv, Tanguy Y. Seiwert, Danielle N. Margalit, Michelle D. Williams, Carly E. A. Barbon, Rene D. Largo, Jon A. Smith, Neil D. Gross
Case presentation A Caucasian male aged 51 years presented with tongue pain, odynophagia, right otalgia, and weight loss. Physical examination showed a tender, ulcerative mass of the posterior lateral tongue and crossing the midline. A biopsy confirmed invasive oral tongue squamous cell carcinoma (SCC). Computed tomography (CT) imaging revealed a deeply invasive tumor involving the right oral tongue
-
Becoming the new editor for CA: The future is now CA: Cancer J. Clin. (IF 254.7) Pub Date : 2024-01-27 Don S. Dizon
CA: A Cancer Journal for Clinicians (CA) was not a journal I ever saw myself publishing in let alone leading; its impact factor and prestige seemed out of reach for me—such is the Imposter Syndrome. Still, I came across the opportunity to become its editor and I applied, thinking I would regret it if I did not at least try. To my delight, I was chosen to succeed Ted Gansler, who had led CA as its editor
-
Most patients with cancer are not undergoing germline genetic testing CA: Cancer J. Clin. (IF 254.7) Pub Date : 2024-01-19 Mike Fillon
“The message is that clinicians should redouble their efforts to identify and test those who are at risk for carrying a genetic alteration that increases the risk of cancer.”Mark E. Robson, MD Science editor Amy H from Santa Clarita, California, was aware of her immediate family’s heavy cancer history so it came as no surprise to her when she was diagnosed with cancer—a stage 1 tumor in the transverse
-
Issue Information CA: Cancer J. Clin. (IF 254.7) Pub Date : 2024-01-19
No abstract is available for this article.
-
More care needed for cancer caregivers CA: Cancer J. Clin. (IF 254.7) Pub Date : 2024-01-19 Mike Fillon
W then ophthalmologist and co-founder of Glaucomflecken LLC, William Flanary, MD, suffered two separate, unrelated bouts of cancer and then cardiac arrest, his wife served as his primary caregiver. While Dr Flanary received the medical attention he needed, Kristin Flanary, also known as Lady Glaucomflecken, co-founder and marketing director of Glaucomflecken LLC in Portland, Oregon, was left frazzled
-
Cancer statistics 2024: All hands on deck CA: Cancer J. Clin. (IF 254.7) Pub Date : 2024-01-17 Don S. Dizon, Arif H. Kamal
The 2024 update to Cancer Statistics from the American Cancer Society estimates that over 2,000,000 people this year will hear the words, “you have cancer.”1 This amounts to nearly 5500 people each day, or the equivalent to one person experiencing this every 15 seconds. This marks the first time incidence has eclipsed 2 million Americans, with more people being diagnosed at earlier stages of these
-
Cancer statistics, 2024 CA: Cancer J. Clin. (IF 254.7) Pub Date : 2024-01-17 Rebecca L. Siegel, Angela N. Giaquinto, Ahmedin Jemal
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries (through 2020) and mortality data collected by the National Center for Health Statistics (through 2021). In 2024, 2,001,140 new cancer cases and
-
Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance CA: Cancer J. Clin. (IF 254.7) Pub Date : 2024-01-04 Raffaella Casolino, Philip A. Beer, Debyani Chakravarty, Melissa B. Davis, Umberto Malapelle, Luca Mazzarella, Nicola Normanno, Chantal Pauli, Vivek Subbiah, Clare Turnbull, C. Benedikt Westphalen, Andrew V. Biankin
The last decade has seen rapid progress in the use of genomic tests, including gene panels, whole-exome sequencing, and whole-genome sequencing, in research and clinical cancer care. These advances have created expansive opportunities to characterize the molecular attributes of cancer, revealing a subset of cancer-associated aberrations called driver mutations. The identification of these driver mutations
-
Opioid analgesics for nociceptive cancer pain: A comprehensive review CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-12-18 Christina Abdel Shaheed, Christopher Hayes, Christopher G. Maher, Jane C. Ballantyne, Martin Underwood, Andrew J. McLachlan, Jennifer H. Martin, Sujita W. Narayan, Mark A. Sidhom
Pain is one of the most burdensome symptoms in people with cancer, and opioid analgesics are considered the mainstay of cancer pain management. For this review, the authors evaluated the efficacy and toxicities of opioid analgesics compared with placebo, other opioids, nonopioid analgesics, and nonpharmacologic treatments for background cancer pain (continuous and relatively constant pain present at
-
American Cancer Society’s report on the status of cancer disparities in the United States, 2023 CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-11-14 Farhad Islami, Jordan Baeker Bispo, Hyunjung Lee, Daniel Wiese, K. Robin Yabroff, Priti Bandi, Kirsten Sloan, Alpa V. Patel, Elvan C. Daniels, Arif H. Kamal, Carmen E. Guerra, William L. Dahut, Ahmedin Jemal
In 2021, the American Cancer Society published its first biennial report on the status of cancer disparities in the United States. In this second report, the authors provide updated data on racial, ethnic, socioeconomic (educational attainment as a marker), and geographic (metropolitan status) disparities in cancer occurrence and outcomes and contributing factors to these disparities in the country
-
Disparities in cancer care: A long way to go CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-11-14 Shail Maingi, Don S. Dizon
The 2023 American Cancer Society (ACS) report on cancer disparities highlights the persistent issues related to inequities in cancer incidences and outcomes.1 Black individuals continue to be diagnosed at higher incidence rates than White individuals with multiple cancers, including colorectal, pancreatic, lung, prostate, and cervical cancers. The report also reveals that Black patients with the same
-
Testicular cancer in 2023: Current status and recent progress CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-11-10 Deaglan J. McHugh, Jack P. Gleeson, Darren R. Feldman
Testicular germ cell tumor (GCT) is the most common solid tumor in adolescent and young adult men. Progress in the management of GCT has been made in the last 50 years, with a substantial improvement in cure rates for advanced disease, from 25% in the 1970s to nearly 80%. However, relapsed or platinum-refractory disease occurs in a proportion, 20% of whom will die from disease progression. This article
-
Issue Information CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-11-04
No abstract is available for this article.
-
To lower cancer risks, study shows that food choices matter CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-11-04 Mike Fillon
It has long been believed—but with few large-scale epidemiological studies to prove it—that ultra-processed foods can contribute to a number of cancers. A new European observational study, based on results from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study, offers more proof validating the issue. The EPIC study goes one step further by showing how diet alternatives
-
MCED blood test boosts cancer detection in symptomatic patients CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-11-04 Mike Fillon
“I think it has to be taken with the caveat that there’s certainly some variability across tumor types. However, if the cost of the test is less of an issue, I think it could be well worth it.”—Wafik El-Deiry MD, PhD A large observational study of patients in England and Wales evaluated the effectiveness of the methylation-based multi-cancer early detection (MCED) blood test Galleri to identify over
-
Reviewer acknowledgement 2023 CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-11-01
In order to maintain the high standards of CA’s content, the Editors of CA rely on the knowledge and dedication of many experts in deciding which topics to pursue, which manuscripts to publish, and what modifications to make to ensure medical and scientific accuracy and suitability for our readers. We thank our Associate Editors and our Editorial Advisory Board, who continue to provide these services
-
Lung cancer diagnosis and mortality beyond 15 years since quit in individuals with a 20+ pack-year history: A systematic review CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-11-01 Karli K. Kondo, Basmah Rahman, Chelsea K. Ayers, Rose Relevo, Jessica C. Griffin, Michael T. Halpern
Current US lung cancer screening recommendations limit eligibility to adults with a pack-year (PY) history of ≥20 years and the first 15 years since quit (YSQ). The authors conducted a systematic review to better understand lung cancer incidence, risk and mortality among otherwise eligible individuals in this population beyond 15 YSQ. The PubMed and Scopus databases were searched through February 14
-
Screening for lung cancer: 2023 guideline update from the American Cancer Society CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-11-01 Andrew M. D. Wolf, Kevin C. Oeffinger, Tina Ya-Chen Shih, Louise C. Walter, Timothy R. Church, Elizabeth T. H. Fontham, Elena B. Elkin, Ruth D. Etzioni, Carmen E. Guerra, Rebecca B. Perkins, Karli K. Kondo, Tyler B. Kratzer, Deana Manassaram-Baptiste, William L. Dahut, Robert A. Smith
Lung cancer is the leading cause of mortality and person-years of life lost from cancer among US men and women. Early detection has been shown to be associated with reduced lung cancer mortality. Our objective was to update the American Cancer Society (ACS) 2013 lung cancer screening (LCS) guideline for adults at high risk for lung cancer. The guideline is intended to provide guidance for screening
-
Screening for lung cancer CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-11-01
The American Cancer Society has updated its guideline for lung cancer screening in people who are at higher risk because of their history of smoking.
-
Lung cancer screening guidelines: Smoking matters, not quitting CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-11-01 Don S. Dizon, Arif H. Kamal
Lung cancer screening is a proven method to detect cancers early, resulting in reduced morbidity and mortality. Guidelines regarding lung cancer screening have been published by a few groups, including the American Cancer Society (ACS) who, since 2010, have recommended for low-dose computed tomography screening for those who meet the criteria. One such criterion is years since quitting (YSQ). The 2023
-
Immunosurveillance in clinical cancer management CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-10-25 Guido Kroemer, Timothy A. Chan, Alexander M. M. Eggermont, Lorenzo Galluzzi
The progression of cancer involves a critical step in which malignant cells escape from control by the immune system. Antineoplastic agents are particularly efficient when they succeed in restoring such control (immunosurveillance) or at least establish an equilibrium state that slows down disease progression. This is true not only for immunotherapies, such as immune checkpoint inhibitors (ICIs), but
-
Locally advanced mismatch repair-deficient gastroesophageal junction cancer: Diagnosis, treatment modifications, and monitoring CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-10-17 Rutika Mehta, Andrew Sinnamon, Aamir Dam, Christine Walko, Russell Palm, Laura Barton, Gregory Lauwers, Jose M. Pimiento
Case presentation CW is a Caucasian woman aged 70 years with history of asthma, sleep apnea (on continuous positive airway pressure), hypertension, and hyperlipidemia who presented to her primary care physician for her annual physical. She was otherwise well and specifically denied any gastrointestinal symptoms or unintentional weight loss. Per patient report and a review of outside records, she underwent
-
Study identifies signs and symptoms of colorectal cancer risk at younger ages CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-09-04 Mike Fillon
“The overarching objective [of this study] is to improve the early detection of CRC at younger ages, which holds significant potential for improving patient outcomes.”—Yin Cao, ScD, MPH Eight years ago, Paula Chambers-Raney from Houston, Texas, suffered from stomach pain, blood in her stool, and anemia. Her primary care physician told her that she had hemorrhoids. Then, over the next 18 months, other
-
Issue Information CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-09-04
No abstract is available for this article.
-
Adding immunotherapy to chemotherapy improves survival for endometrial cancer patients CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-09-04 Mike Fillon
There is encouraging news for patients with endometrial cancer based on the results of two recent phase 3 clinical trials: Immunotherapy combined with chemotherapy may appreciably increase progression-free survival for patients with advanced or recurrent endometrial cancer. Both trials—NRG-GY018 and RUBY— were presented at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer in
-
The evolving landscape of salivary gland tumors CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-07-25 Conor E. Steuer, Glenn J. Hanna, Kartik Viswanathan, James E. Bates, Azeem S. Kaka, Nicole C. Schmitt, Alan L. Ho, Nabil F. Saba
Salivary gland cancers are a rare, histologically diverse group of tumors. They range from indolent to aggressive and can cause significant morbidity and mortality. Surgical resection remains the mainstay of treatment, but radiation and systemic therapy are also critical parts of the care paradigm. Given the rarity and heterogeneity of these cancers, they are best managed in a multidisciplinary program
-
Issue Information CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-07-03
No abstract is available for this article.
-
Clinicians need to stay current with polypharmacy concerns CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-07-03 Mike Fillon
Anew study raises an alarm over polypharmacy, an issue that is not new but may become more worrisome because of an aging population and a myriad of new drugs coming to market, including cancer drugs. The study appears in Cancer (doi:10.1002/cncr.34642). Corresponding author Erika Ramsdale, MD, MS, geriatric oncologist and associate professor of hematology/oncology in the Department of Medicine at the
-
Does distance deter male fertility preservation? CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-07-03 Mike Fillon
“Fertility preservation is about preserving your future options so that you aren’t taking options away from your future self. In this complicated context, living a long distance from the fertility preservation clinic can become yet another barrier, and clinicians can help patients by strategizing with them about ways to overcome such logistical challenges.”—Timothy D. Gilligan, MD For patients with
-
Patient navigation across the cancer care continuum: An overview of systematic reviews and emerging literature CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-06-26 Raymond J. Chan, Vivienne E. Milch, Fiona Crawford-Williams, Oluwaseyifunmi Andi Agbejule, Ria Joseph, Jolyn Johal, Narayanee Dick, Matthew P. Wallen, Julie Ratcliffe, Anupriya Agarwal, Larissa Nekhlyudov, Matthew Tieu, Manaf Al-Momani, Scott Turnbull, Rahul Sathiaraj, Dorothy Keefe, Nicolas H. Hart
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the
-
Isn’t there enough evidence on the benefits of patient navigation? CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-06-26 Electra D. Paskett, Tracy Battaglia, Elizabeth A. Calhoun, Michelle C. Chappell, Andrea Dwyer, Linda G. Fleisher, Jennifer Greenwald, Kristen J. Wells
In this issue of CA: A Cancer Journal for Clinicians, Chan and colleagues1 describe an umbrella review of 61 systematic reviews published between 2012 and 2022, along with a review of 53 primary studies published globally since 2021. Patient navigation (PN) has many definitions, and, in this, review PN was defined according to the definition of Wells et al.2 combined with that of Dalton et al.,3 which
-
Survival outcomes used to validate version 9 of the American Joint Committee on Cancer staging system for appendiceal cancer CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-06-26 Lauren M. Janczewski, Amanda E. Browner, Joseph H. Cotler, Heidi Nelson, Sanjay Kakar, Norman J. Carr, Nader N. Hanna, Andreana N. Holowatyj, Richard M. Goldberg, M. Kay Washington, Elliot A. Asare, Michael J. Overman
The standard for cancer staging in the United States for all cancer sites, including primary carcinomas of the appendix, is the American Joint Committee on Cancer (AJCC) staging system. AJCC staging criteria undergo periodic revisions, led by a panel of site-specific experts, to maintain contemporary staging definitions through the evaluation of new evidence. Since its last revision, the AJCC has restructured
-
Implementation in action: Collaborating on the transition to primary HPV screening for cervical cancer in the United States CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-06-22 Levi S. Downs, Ritu Nayar, Jane Gerndt, Debbie Saslow
In July 2020, the American Cancer Society (ACS) released an updated cervical cancer screening guideline calling for primary human papillomavirus (HPV) screening as the preferred strategy.1 Primary HPV screening refers to cervical cancer screening with an HPV test alone as the initial screening modality. Under this strategy, cervical cytology is reserved for use as one option for a triage test should
-
Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-06-17 Zsolt Megyesfalvi, Carl M. Gay, Helmut Popper, Robert Pirker, Gyula Ostoros, Simon Heeke, Christian Lang, Konrad Hoetzenecker, Anna Schwendenwein, Kristiina Boettiger, Paul A. Bunn, Ferenc Renyi-Vamos, Karin Schelch, Helmut Prosch, Lauren A. Byers, Fred R. Hirsch, Balazs Dome
Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity. It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority of SCLCs exhibit neuroendocrine features, an important subset of tumors lacks these properties. Genomic profiling of SCLC reveals genetic instability, almost universal inactivation of the tumor suppressor genes TP53
-
Social determinants of health and US cancer screening interventions: A systematic review CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-06-17 Ariella R. Korn, Callie Walsh-Bailey, Margarita Correa-Mendez, Peter DelNero, Meagan Pilar, Brittney Sandler, Ross C. Brownson, Karen M. Emmons, April Y. Oh
There remains a need to synthesize linkages between social determinants of health (SDOH) and cancer screening to reduce persistent inequities contributing to the US cancer burden. The authors conducted a systematic review of US-based breast, cervical, colorectal, and lung cancer screening intervention studies to summarize how SDOH have been considered in interventions and relationships between SDOH
-
Virtual Tumor Board: Papillary thyroid carcinoma with nodal disease CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-06-14 Peter J. Abraham, Rongzhi Wang, Deepti Bahl, Pradeep Bhambhvani, Sadie Ho, Jessica M. Fazendin, Herbert Chen, Brenessa M. Lindeman
Case presentation and overview The patient is a 19-year-old female who had an incidental thyroid nodule discovered on magnetic resonance imaging (MRI) in July 2020 during the work-up of a superficial, midline neck cellulitis. She reported having noticed a bulge in her neck a few years prior but had never been concerned about it. She began seeing an endocrinologist and underwent a thyroid ultrasound
-
Multidisciplinary approach for a high-risk, localized soft tissue sarcoma of the trunk after unplanned nononcological resection CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-05-24 Candace L. Haddox, Elizabeth H. Baldini, Jyothi P. Jagannathan, Jason L. Hornick, Chandrajit P. Raut
Case presentation A man aged 45 years with hypertension and hyperlipidemia presented to his primary care physician with a 3-month history of a golf ball-sized right upper back mass. Ultrasound was performed, revealing a well defined lesion with mixed echogenicity, thought to be consistent with a lipoma. Clinically, however, the mass rapidly enlarged and became painful. The patient was referred to dermatology
-
The future of cancer care at home: Findings from an American Cancer Society summit CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-05-24 Arif H. Kamal, Paul P. Thienprayoon, Marco H. M. Janssen, Lisa A. Lacasse, William L. Dahut, Justin E. Bekelman
In February 2022, the White House announced the reignition of the Cancer Moonshot Initiative with the goals of reducing the death rate from cancer by at least 50% over the next 25 years and improving the experience of people and their families living with and surviving cancer. A core component of the Cancer Moonshot Initiative is the facilitation of multisector partnerships to solve the compelling
-
Clinical practice guideline and expert consensus recommendations for rehabilitation among children with cancer: A systematic review CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-05-09 Allison J. L’Hotta, Samantha B. Randolph, Ben Reader, Kim Lipsey, Allison A. King
Increased attention to the rehabilitation needs of children with cancer is vital to enhance health, quality-of-life, and productivity outcomes. Among adults with cancer, rehabilitation recommendations are frequently incorporated into guidelines, but the extent to which recommendations exist for children is unknown. Reports included in this systematic review are guideline or expert consensus reports
-
Issue Information CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-05-04
No abstract is available for this article.
-
Why young patients with cancer refuse the human papillomavirus vaccine CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-05-04 Mike Fillon
Despite their elevated risk for developing cervical, oropharyngeal, and other human papillomavirus (HPV)–related cancers and the strong and consistent evidence for the HPV vaccine’s safety and efficacy, many young cancer survivors reject this vaccine. In a new study appearing in Cancer, researchers from Emory University School of Medicine and the Aflac Cancer & Blood Disorders Center (both in Atlanta
-
Better solutions needed to reduce suicides among patients with cancer CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-05-04 Mike Fillon
“Our findings illustrate that suicide is an important risk following cancer surgery and highlight the need to develop and implement distress screening programs in surgical oncology practices.” —Chi-Fu Jeffrey Yang, MD A new study finds that patients with cancer who have under gone surgery have a greater suicide risk than the general population. Also, the researchers found that patients with deadlier
-
Survival outcomes used to generate version 9 American Joint Committee on Cancer staging system for anal cancer CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-04-28 Lauren M. Janczewski, Joseph Faski, Heidi Nelson, Marc J. Gollub, Cathy Eng, James D. Brierley, Joel M. Palefsky, Richard M. Goldberg, M. Kay Washington, Elliot A. Asare, Karyn A. Goodman
The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including anal cancer, is the standard for cancer staging in the United States. The AJCC staging criteria are dynamic, and periodic updates are conducted to optimize AJCC staging definitions through a panel of experts charged with evaluating new evidence to implement changes. With greater availability of large data sets
-
Multidisciplinary management in the treatment of intrahepatic cholangiocarcinoma CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-04-12 Samantha M. Ruff, Dayssy A. Diaz, Kenneth L. Pitter, Bridget C. Hartwell, Timothy M. Pawlik
Case presentation A 63-year-old woman who was a former smoker with a past medical history of hypertension and gastroesophageal reflux disease initially presented with upper abdominal pain. Her family history was notable for breast cancer in her mother, lung cancer in her father, and renal cell carcinoma in her sister. An ultrasound showed a heterogenous mass in the left lobe of the liver measuring
-
From medical student to Editor: A note of thanks CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-03-30 Ted Gansler
I first encountered CA: A Cancer Journal for Clinicians as a medical student. Back then, the American Cancer Society (ACS) printed hundreds of thousands of copies that were mailed (without any charge) to practicing physicians and dropped off by ACS volunteers at medical schools, with the goals of educating students about cancer and inspiring some of us to pursue careers in cancer-related specialties
-
Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-03-20 Laura A. Huppert, Ozge Gumusay, Dame Idossa, Hope S. Rugo
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine
-
Issue Information CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-03-03
No abstract is available for this article.
-
Cancer survivors at greater risk for bone fractures late in life CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-03-03 Mike Fillon
Cancer survivors may be more susceptible to frailty-related bone fractures to the pelvis and vertebrae according to a study by American Cancer Society (ACS) researchers. “Prior to our study, there was some evidence to suggest that cancer survivors may be at a higher risk of bone fractures,” says Erika Rees-Punia, PhD, MPH, senior principal scientist of the Department of Population Science at the ACS
-
Near majority of adults favor R ratings for films with smoking CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-03-03 Mike Fillon
There is compelling evidence of a causal relationship between depictions of cigarette smoking in movies and youth smoking initiation. —Kelly D. Blake, ScD A new study finds that a near majority of adults favor R ratings for movies that show actors smoking. R ratings restrict viewing by people younger than 17 years without an accompanying parent or adult guardian. The study appears in the American Journal
-
Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-03-01 Adam H. Fox, Mizuki Nishino, Raymond U. Osarogiagbon, M. Patricia Rivera, Lauren S. Rosenthal, Robert A. Smith, Farhood Farjah, Lynette M. Sholl, Gerard A. Silvestri, Bruce E. Johnson
Advances in biomarker-driven therapies for patients with nonsmall cell lung cancer (NSCLC) both provide opportunities to improve the treatment (and thus outcomes) for patients and pose new challenges for equitable care delivery. Over the last decade, the continuing development of new biomarker-driven therapies and evolving indications for their use have intensified the importance of interdisciplinary
-
Colorectal cancer statistics, 2023 CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-03-01 Rebecca L. Siegel, Nikita Sandeep Wagle, Andrea Cercek, Robert A. Smith, Ahmedin Jemal
Colorectal cancer (CRC) is the second most common cause of cancer death in the United States. Every 3 years, the American Cancer Society provides an update of CRC statistics based on incidence from population-based cancer registries and mortality from the National Center for Health Statistics. In 2023, approximately 153,020 individuals will be diagnosed with CRC and 52,550 will die from the disease
-
Translating energy balance research from the bench to the clinic to the community: Parallel animal-human studies in cancer CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-02-24 Miriam B. Garcia, Keri L. Schadler, Joya Chandra, Steven K. Clinton, Kerry S. Courneya, Zobeida Cruz-Monserrate, Carrie R. Daniel, Andrew J. Dannenberg, Wendy Demark-Wahnefried, Mark W. Dewhirst, Carol J. Fabian, Stephen D. Hursting, Melinda L. Irwin, Neil M. Iyengar, Jennifer L. McQuade, Kathryn H. Schmitz, Karen Basen-Engquist
Advances in energy balance and cancer research to date have largely occurred in siloed work in rodents or patients. However, substantial benefit can be derived from parallel studies in which animal models inform the design of clinical and population studies or in which clinical observations become the basis for animal studies. The conference Translating Energy Balance from Bench to Communities: Application
-
Cancer statistics, 2023 CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-01-12 Rebecca L. Siegel, Kimberly D. Miller, Nikita Sandeep Wagle, Ahmedin Jemal
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries and mortality data collected by the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected
-
Issue Information CA: Cancer J. Clin. (IF 254.7) Pub Date : 2023-01-12
No abstract is available for this article.